# Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis

> **NCT04559412** · PHASE1 · UNKNOWN · sponsor: **Sorrento Therapeutics, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DEVICE:** Sofusa DoseConnect
- **DRUG:** Enbrel

## Key facts

- **NCT ID:** NCT04559412
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-15
- **Primary completion:** 2024-01
- **Final completion:** 2024-12
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04559412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04559412, "Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04559412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*